Cancer

News

Bayer files prostate cancer drug darolutamide with EU regula...

After filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer drug darolutamide.

News

Merck KGaA admits to 'challenging' 2018, as currencies hit s...

Germany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and the company struggling to convince shareholders at semiconductor Versum firm

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Keytruda could get patient-friendly 6 week dosing schedule i...

US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb

News

Gilead expands CAR-T deal with MaxCyte, Precision files for ...

It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-sh

News

Bayer files prostate cancer drug darolutamide in Japan

Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.

News

Advisers urge FDA to delay decision on Karyopharm cancer dru...

Advisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination should be delayed until the results of a phase 3 trial, due late this

Bayer files prostate cancer drug darolutamide with EU regula...

Merck KGaA admits to 'challenging' 2018, as currencies hit s...

Keytruda could get patient-friendly 6 week dosing schedule i...

Gilead expands CAR-T deal with MaxCyte, Precision files for ...

Bayer files prostate cancer drug darolutamide in Japan

Advisers urge FDA to delay decision on Karyopharm cancer dru...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks